HOUSTON INNOVATORS PODCAST EPISODE 64

Houston expert shares how COVID-19 has affected venture capital locally and beyond

Blair Garrou joins the Houston Innovators Podcast to discuss venture capital investing in 2020. Photo via mercuryfund.com

Locally, Blair Garrou, managing director at Mercury Fund, was among the first in the Houston innovation ecosystem to recognize what COVID-19 could do to the world of venture capital, innovation, and more.

At a panel for Houston Exponential's Tech Rodeo on March 6, Garrou observed that the pandemic had the potential to affect the venture capital market regarding valuations and investing.

"I never expected what happened, I just expected the markets to correct," says Garrou on this week's episode of the Houston Innovators Podcast.

While the pandemic posed challenges for startups and investors alike, Garrou says he sees some silver linings to how COVID-19 affected tech adoption. Non-tech and innovation companies have lost a lot of value, according to the S&P 500 Index, but tech and innovation companies have doubled their values. Some experts say that the pandemic has pushed user adoption by a decade or more.

"Everyone finally understands that digital transformation and automation are here to stay," Garrou says. "Just look at our backyard and what the oil and gas industry has gone through. ... I don't think anyone could have through through all of this, but it's put tech ecosystems on notice because what's happened since the end of April to December is unprecedented in the tech space."

With so much uncertainty, it's safe to say the volume of venture capital investing is down, but over the past several months, VC activity has returned, Garrou says. Now, Garrou says he sees later stage deals — like series C rounds — are down, but early stage investing is up as individual investors want in on tech.

"People are realizing that money is in innovation and tech — especially in software," Garrou says. "I can't tell you how many individual investors who call interested in investing in Mercury as a fund or our companies. People are not getting the return they desire from the markets and they are seeing tech companies do great things."

Garrou shares more about what all he's keeping a close eye on as we enter a new year, plus what's happening at Mercury Fund in the episode. Listen to the full interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.


Trending News

Building Houston

 
 

Veronica Wu, founder of First Bight Ventures, recently announced new team members and her hopes for making Houston a leader in synthetic biology. Photo courtesy of First Bight Ventures

Since launching earlier this year, a Houston-based venture capital firm dedicated to investing in synthetic biology companies has made some big moves.

First Bight Ventures, founded by Veronica Wu, announced its growing team and plans to stand up a foundry and accelerator for its portfolio companies and other synthetic biology startups in Houston. The firm hopes to make Houston an international leader in synthetic biology.

“We have a moment in time where we can make Houston the global epicenter of synthetic biology and the bio economy," Wu says to a group of stakeholders last week at First Bight's Rocketing into the Bioeconomy event. "Whether its energy, semiconductor, space exploration, or winning the World Series — Houstonians lead. It’s in our DNA. While others look to the stars, we launch people into space.”

At First Bight's event, Wu introduced the company's new team members. Angela Wilkins, executive director of the Ken Kennedy Institute at Rice University, joined First Bight as partner, and Serafina Lalany, former executive director of Houston Exponential, was named entrepreneur in residence. Carlos Estrada, who has held leadership positions within WeWork in Houston, also joins the team as entrepreneur in residence and will oversee the company's foundry and accelerator that will be established to support synthetic biology startups, Wu says.

“First Bight is investing to bring the best and the brightest — and most promising — synthetic biology startups from around the country to Houston," Wu continues.

First Bighthas one seed-staged company announced in its portfolio. San Diego-based Persephone Biosciences was founded in 2017 by synthetic and metabolic engineering pioneers, Stephanie Culler and Steve Van Dien. The company is working on developing microbial products that impact patient and infant health.

Wu, who worked at Apple before the launch of the iPhone and Tesla before Elon Musk was a household name, says she saw what was happening in Houston after her brother moved to town. She first invested in Houston's synthetic biology ecosystem when she contributed to one of Solugen's fundraising rounds. The alternative plastics company is now a unicorn valued at over $1 billion.

“I founded First Bight because of what I see is the next great wave of technology innovation," she says at the event. "I founded it in Houston because the pieces are right here.”

Trending News